Insight Brief
December 06, 2016

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach
Comprehensive genomic strategies are needed to support immuno-oncology clinical development programs. Genomics is a key tool that such programs can embrace to help understand and elucidate the individual response signatures to immuno-oncology therapies. Given the advent of a myriad of combination studies with additional biological complexity, genomics can play a key role in understanding T-cell functions and tumor factors that contribute to efficacy, safety and resistance outcomes. Such applications can include baseline assessments prior to therapy to drive patient selection but also longitudinal sampling to monitor treatment response by examining the genetic signatures over time.

Download our complimentary insight brief to learn how our genomics-based biomarker approaches can empower the success of your immuno-oncology clinical development programs by implementing a tailored biomarker strategy.

Wendell Jones, Ph.D., Principal Bioinformaticist and Scientific Advisor, Q2 Solutions | EA Genomics
Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics, Q2 Solutions | EA Genomics

Related Services:
Genomic Assays for Clinical Development

Identifying the right approach from a wealth of potential options

Read More